Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3066318 | 0.91 | MTNR1A (0.35) | HTTALDH1A1HPGD | |
| SCHEMBL12792113 | 0.85 | CCNE2 (0.41) | GAAHTTGPR55KDM4EALDH1A1 | |
| SCHEMBL12792077 | 0.85 | CCNE2 (0.41) | GAAHTTGPR55KDM4EALDH1A1 | |
| SCHEMBL5325131 | 0.77 | SOS1 (0.40) | GPR55KDM4EALDH1A1HPGD | |
| SCHEMBL5331797 | 0.77 | NPC1 (0.45) | HTTNPSR1ALDH1A1HPGD | |
| SCHEMBL3072336 | 0.77 | SOS1 (0.41) | GPR55KDM4EALDH1A1HPGD | |
| SCHEMBL5325178 | 0.76 | MAPT (0.34) | GAAHTTNPSR1GPR55 | |
| SCHEMBL13138600 | 0.76 | ADORA2A (0.36) | ALDH1A1SLC2A1 | |
| SCHEMBL3076140 | 0.74 | ADORA2A (0.41) | SLC2A1 | |
| SCHEMBL5331793 | 0.72 | EGFR (0.33) | ALDH1A1SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790882-B2 | Monophosphine compound, transition metal complex thereof and production method of optically active compound using the complex as asymmetric catalyst | Carreira, Erick M. (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20050277772-A1 | Monophosphine compound, transition metal complex thereof and production method of optically active compound using the complex as asymmetric catalyst | Carreira, Erick (CH) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277772-A1 | Monophosphine compound, transition metal complex thereof and production method of optically active compound using the complex as asymmetric catalyst | C1R, ARL1, C5 | GAA 3565/4885HTT 3950/4885NPSR1 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.